Cannabis Firm Reports Results of First Trial For Cannabinoid-Based Sleep Medicine • High Times

  • An Australian medical cannabis company is trumpeting the results of a clinical trial for its insomnia treatment.
  • Zelira Therapeutics said last week that it received the final report for its proprietary cannabis formulation known as ZTL-101, and that its findings represent a world-first clinical validation of the treatment as being safe and effective in combating chronic insomnia.
  • According to Zelira, the analysis showed treated patients slept significantly longer, went to sleep faster and went back to sleep sooner after waking, while those same patients also reported significant improvement in quality of life measures including feeling rested after sleep, feeling less stressed, less fatigued and improved overall functioning.
  • The fact that ZLT-101 treatment achieved statistically significant, dose responsive improvements across a broad range of key insomnia indices is impressive, particularly given the relatively short two-week dosing window, Eastwood said in a statement.

Read full article: